Atherosclerosis Targeting Module Development Service
Overview Atherosclerosis Targeting Module Development What Can We Do for You? Workflow FAQs
Creative Biolabs provides expert drug delivery options designed to treat atherosclerosis. Our delivery systems based on liposomes and lipid nanoparticles work with targeted peptides and antibodies together with aptamers to deliver therapeutic agents exactly to atherosclerotic plaques. We dedicate our team to delivering top-notch services that remain affordable while supporting both your research endeavors and preclinical applications. Please reach out to us to learn more details.
Contact our team to get an inquiry now!
Overview
Atherosclerosis develops as plaque composed of fats and cholesterol accumulates within arteries which leads to arterial narrowing and hardening. Slowed blood flow and an elevated risk of cardiovascular conditions like heart attack, stroke, and peripheral artery disease result from this process. The treatment protocol for this condition requires patients to make lifestyle adjustments and use medications alongside surgical procedures when necessary. Conventional therapies struggle to reach maximum effectiveness because they fail to focus directly on plaques or damaged arterial regions. Treatment outcomes for atherosclerosis improve by combining targeting modules with drug/module delivery systems (TDDS). Module delivery systems such as liposomes and lipid nanoparticles (LNPs) and exosomes enable therapeutic agents to reach arterial plaques directly which enhances both drug bioavailability and stability. Drug delivery systems utilize targeting modules like peptides including CPPs and HPs along with antibodies and aptamers to direct treatments precisely to areas where plaque forms. ADCs and PDCs enhance therapeutic outcomes while minimizing adverse effects by targeting drug delivery directly to plaques.
Fig. 1 Nanoparticle targeting atherosclerotic plaques in mouse models.1
Atherosclerosis Targeting Delivery Systems
The development of atherosclerosis involves chronic inflammation resulting in cholesterol buildup and lipid deposits combined with cellular debris which form plaques along artery walls. The accumulation of arterial plaque results in arterial constriction which hardens the blood vessels thereby diminishing blood flow and raising the probability of heart attacks and strokes as well as other cardiovascular conditions. Successful treatments for atherosclerosis work by diminishing lipid deposits together with arterial inflammation. TDDS delivers treatment agents directly to plaque accumulation areas for enhanced therapeutic benefits and fewer side effects. Below is a list of common TDDS, each designed to address unique therapeutic needs and improve outcomes.
Table 1. The Primary Types of TDDS Utilized in The Treatment of Atherosclerosis
|
TDDS Type
|
Description
|
Targeting Mechanism
|
Applications
|
|
Nanoparticles
|
Small particles (1-1000 nm) that can encapsulate lipophilic or hydrophilic drugs and deliver them efficiently.
|
Targeting via surface modifications with ligands specific to endothelial cells or macrophages in plaques.
|
Anti-inflammatory therapy, lipid-lowering therapy, gene delivery.
|
|
Liposomes
|
Lipid-based vesicles designed to carry both hydrophilic and hydrophobic drugs, enhancing drug stability.
|
Targeting specific receptors on endothelial cells or macrophages, such as scavenger receptors.
|
Drug delivery, anti-inflammatory therapies, gene therapy.
|
|
Antibody-Drug Conjugates (ADCs)
|
Monoclonal antibodies conjugated to cytotoxic drugs, enabling selective delivery to atherosclerotic plaques.
|
Targeting via antibodies specific to plaque-associated antigens or endothelial cell markers.
|
Targeted therapy for plaque reduction, anti-inflammatory treatments.
|
|
Cell-Penetrating Peptides (CPPs)
|
Short peptides that facilitate direct drug or gene entry into cells.
|
Enhancing drug or gene uptake into endothelial cells or macrophages in plaques.
|
Drug delivery, gene therapy, reducing plaque burden.
|
|
Polymer Nanocapsules
|
Biodegradable polymer-based nanocapsules designed for controlled release of drugs.
|
Surface-targeted delivery to macrophages or endothelial cells in the plaque.
|
Lipid-lowering drugs, anti-inflammatory therapy, sustained release.
|
|
Nanogels
|
Hydrophilic polymer networks that encapsulate drugs and swell in water for controlled release.
|
Active targeting via specific ligands for plaques or endothelial cells.
|
Targeted drug delivery, anti-inflammatory treatments for plaque stabilization.
|
Targeting ligands are critical in the development of targeted drug delivery systems, as they enable the precise delivery of therapeutic agents to specific cells or tissues. These ligands bind selectively to receptors or molecules on the surface of target cells, ensuring that the drug reaches the intended site of action. By improving the accuracy of drug delivery, targeting ligands help to maximize treatment efficacy and minimize unwanted side effects. Below is a list of commonly used targeting ligands, highlighting their applications and therapeutic potential.
Table 2. Targeting Ligands Used in Preclinical Studies for Atherosclerosis
|
Targeting Ligand
|
Target
|
Mechanism of Action
|
Research Focus
|
|
Oxidized LDL (oxLDL)
|
Oxidized low-density lipoprotein (oxLDL)
|
Antibodies or aptamers targeting oxLDL
|
Selective targeting of macrophages that internalize oxLDL, a hallmark of atherosclerosis.
|
|
VCAM-1 (Vascular Cell Adhesion Molecule-1)
|
VCAM-1 receptor on endothelial cells
|
Antibodies, aptamers, or peptides targeting VCAM-1
|
Targets the endothelial cells involved in plaque formation and inflammation.
|
|
P-selectin
|
P-selectin (expressed on activated platelets and endothelial cells)
|
Monoclonal antibodies or peptides targeting P-selectin
|
Involved in leukocyte recruitment to inflamed sites, promoting plaque formation.
|
|
Mannose Receptor (CD206)
|
Macrophages with mannose receptors
|
Antibodies or nanoparticles targeting CD206
|
Targets macrophages involved in plaque formation and foam cell creation.
|
|
CD11b/CD18 (Integrins)
|
Macrophages and monocytes
|
Peptides or antibodies targeting integrins
|
Targets immune cells involved in inflammation and plaque development.
|
|
CD36
|
Macrophages and foam cells
|
Antibodies or peptides targeting CD36
|
Selectively targets macrophages that engulf lipids, contributing to foam cell formation.
|
|
Toll-like Receptor 4 (TLR4)
|
Inflammatory macrophages and endothelial cells
|
Peptides or antibodies targeting TLR4
|
Targets inflammatory pathways that accelerate atherosclerotic plaque formation.
|
|
Scavenger Receptor A (SR-A)
|
Macrophages
|
Antibodies targeting SR-A receptor
|
Targets macrophages involved in the uptake of modified lipoproteins and plaque buildup.
|
Experience the Creative Biolabs Advantage - Get a Quote Today
What Can We Do for You?
Atherosclerosis Treatment
Creative Biolabs offers high-quality targeted delivery services specifically designed to address atherosclerosis treatment.
Personalized Solutions for Your Needs
Our team provides tailored solutions that meet your specific requirements, ensuring the most effective delivery of therapeutic agents.
Contact Us for More Information
If our services interest you, please feel free to reach out for more details. We are here to support you throughout the entire project.
Workflow
FAQ
Q: What types of targeting modules do you offer for atherosclerosis?
A: We provide various targeting modules including peptides, antibodies, aptamers, and small molecules designed to selectively bind to atherosclerotic plaques, endothelial cells, or inflammatory cells within the lesion sites.
Q: What technologies do you use in the development of targeting modules?
A: We utilize a variety of advanced technologies such as phage display, antibody engineering, and nanoparticle conjugation. We also employ in silico models and animal models for efficacy testing and validation.
Q: What types of diseases can be treated using these targeted modules?
A: Our atherosclerosis targeting modules are primarily designed for the treatment of atherosclerosis and related cardiovascular diseases such as myocardial infarction, stroke, and peripheral artery disease.
Q: Can your targeting modules be combined with drug delivery systems?
A: Yes, our targeting modules can be integrated with advanced drug delivery systems such as liposomes, nanoparticles, and lipid-polymer hybrid nanoparticles to enhance therapeutic outcomes and optimize drug release profiles.
Reference
-
Pang, Alexander Shao-Rong et al. "Nanoparticles as Drug Delivery Systems for the Targeted Treatment of Atherosclerosis." Molecules (Basel, Switzerland)vol. 29,12 2873. 17 Jun. 2024, DOI:10.3390/molecules29122873. Distributed under Open Access license CC BY 4.0, without modification.
Our services are For Research Use Only. We do not provide services to individuals.
